Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals (TSE:MDP)
:MDP
RESEARCH TOOLSreports
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.47 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)119.09K
Market Cap
C$82.76M
Enterprise ValueC$130.64M
Total Cash (Recent Filing)$8.44M
Total Debt (Recent Filing)$39.91M
Price to Earnings (P/E)13.0
Beta1.05
Next Earnings
Jul 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding32,202,250
10 Day Avg. Volume63,343
30 Day Avg. Volume119,089
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.56
Price to Cash Flow (P/CF)2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.20
Enterprise Value/Ebitda7.07
Forecast
1Y Price Target
C$5.62Price Target Upside118.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Launches GRAFAPEX in US, Eyes $100M Revenue
PremiumCompany Announcements
Medexus Pharmaceuticals: Robust Earnings Amidst Challenges
PremiumCompany Announcements
Medexus Secures Ontario Public Reimbursement for Trecondyv
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMedexus's FQ3 results were ahead of initial estimates, showing strong performance.
Regulatory ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.
Bears Say
Market CompetitionThere is generic risk in the base business with Rupall losing exclusivity.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.38% Insiders
0.40% Mutual Funds
0.03% Other Institutional Investors
92.18% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals’s price range in the past 12 months?
Medexus Pharmaceuticals lowest stock price was C$1.47 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals’s market cap?
Medexus Pharmaceuticals’s market cap is C$82.76M.
When is Medexus Pharmaceuticals’s upcoming earnings report date?
Medexus Pharmaceuticals’s upcoming earnings report date is Jul 01, 2025 which is in 110 days.
How were Medexus Pharmaceuticals’s earnings last quarter?
Medexus Pharmaceuticals released its earnings results on Feb 05, 2025. The company reported C$0.043 earnings per share for the quarter, missing the consensus estimate of C$0.052 by -C$0.009.
Is Medexus Pharmaceuticals overvalued?
According to Wall Street analysts Medexus Pharmaceuticals’s price is currently Undervalued.
Does Medexus Pharmaceuticals pay dividends?
Medexus Pharmaceuticals does not currently pay dividends.
What is Medexus Pharmaceuticals’s EPS estimate?
Medexus Pharmaceuticals’s EPS estimate is -0.1.
How many shares outstanding does Medexus Pharmaceuticals have?
Medexus Pharmaceuticals has 32,202,250 shares outstanding.
What happened to Medexus Pharmaceuticals’s price movement after its last earnings report?
Medexus Pharmaceuticals reported an EPS of C$0.043 in its last earnings report, missing expectations of C$0.052. Following the earnings report the stock price went down -19.525%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$5.62 (118.68% Upside)
C$5.62 (118.68% Upside)
Insider Transactions
Bought Shares
Worth C$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.92%
12-Months-Change
Fundamentals
Return on Equity
11.27%
Trailing 12-Months
Asset Growth
-0.72%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
---
MDP Stock 12 Month Forecast
Average Price Target
C$5.62
▲(118.68% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering MDP
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+27.14%
reiterated a buy rating last month
Copying David Martin PhD's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +27.14% per trade.
---